<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03981211</url>
  </required_header>
  <id_info>
    <org_study_id>VHCRP1902</org_study_id>
    <nct_id>NCT03981211</nct_id>
  </id_info>
  <brief_title>Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs</brief_title>
  <acronym>TOPIC</acronym>
  <official_title>Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Strategic Therapeutic Intervention to Enhance Linkage to Care in People Who Inject Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the proportion of patients achieving confirmed SVR12 (undetectable&#xD;
      HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for&#xD;
      IRID (injecting related infectious diseases) and commencing inpatient DAA treatment within&#xD;
      public hospital services.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted as a Phase IV, multicentre, sequential cohort trial.&#xD;
&#xD;
      60 participants will be enrolled from participating hospital inpatient services. They will be&#xD;
      evaluated for eligibility by the use of rapid point-of-care (POC) confirmation of viraemia in&#xD;
      people who inject drugs (PWID) hospitalised for IRID. The period of hospitalisation for&#xD;
      management of IRID, particularly when prolonged, may represent an ideal opportunity to engage&#xD;
      HCV-infected PWID and a potential important strategy for broader HCV elimination.&#xD;
&#xD;
      Eligible patients will be enrolled into one of two treatment cohorts A and B.&#xD;
&#xD;
      A) 30 patients will immediately commence treatment whilst an inpatient of G/P&#xD;
      (glecaprevir/pibrentasvir) with continuation of therapy and follow-up in viral hepatitis&#xD;
      services post discharge (standard duration therapy).&#xD;
&#xD;
      Following the successful completion of Cohort A, eligible patients will be enrolled into&#xD;
      Cohort B.&#xD;
&#xD;
      B) 30 patients will immediately commence treatment whilst an inpatient of 4 weeks of SOF/G/P&#xD;
      (sofosbuvir/glecaprevir/pibrentasvir) with continuation of therapy and follow-up in viral&#xD;
      hepatitis services post discharge (short duration therapy).&#xD;
&#xD;
      Any patient with recurrent viraemia during follow-up will be genotyped +/- sequenced to&#xD;
      exclude re-infection. If relapse is confirmed the patient will be offered re-treatment with&#xD;
      standard of care (SOC) salvage therapy based on results of resistance testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Anticipated">February 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12 outcomes for all total patient population</measure>
    <time_frame>12 weeks post completion of commenced treatment</time_frame>
    <description>To evaluate the proportion of patients achieving confirmed SVR12 (undetectable HCV RNA at time point 12 weeks plus post treatment commencement) in patients hospitalised for IRID and commencing inpatient DAA treatment within public hospital services.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Liver Inflammation</condition>
  <condition>Liver Cirrhoses</condition>
  <arm_group>
    <arm_group_label>Cohort A: 8 weeks G/P standard therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks treatment of a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (standard duration therapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: 4 weeks SOF/G/P shortened therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks treatment of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily with food (shortened duration therapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet</intervention_name>
    <description>8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily</description>
    <arm_group_label>Cohort A: 8 weeks G/P standard therapy</arm_group_label>
    <arm_group_label>Cohort B: 4 weeks SOF/G/P shortened therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet</intervention_name>
    <description>4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily</description>
    <arm_group_label>Cohort B: 4 weeks SOF/G/P shortened therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must meet all of the following inclusion criteria to be eligible to&#xD;
        participate in this study.&#xD;
&#xD;
          1. Have voluntarily signed the informed consent form.&#xD;
&#xD;
          2. 18 years of age or older.&#xD;
&#xD;
          3. Injected drugs within the last 6 months&#xD;
&#xD;
          4. Hospitalised with an IRID with an anticipated inpatient stay of &gt; 1 week&#xD;
&#xD;
             Participants must meet the following additional inclusion criteria to be treated in&#xD;
             this study.&#xD;
&#xD;
          5. HCV RNA positive&#xD;
&#xD;
          6. Compensated liver disease&#xD;
&#xD;
          7. Documented non-cirrhotic at enrolment with a qualifying liver FibroScan ≤ 9.5 kpA&#xD;
&#xD;
          8. If co-infection with HIV is documented, the subject must meet the following criteria:&#xD;
&#xD;
               1. ART naïve with CD4 T cell count &gt;500 cells/mm3; OR&#xD;
&#xD;
               2. On a stable ART regimen (containing only permissible ART) for &gt;4 weeks prior to&#xD;
                  screening visit, with CD4 T cell count ≥200 cells/mm3 and a plasma HIV RNA level&#xD;
                  below the limit of detection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants who meet any of the exclusion criteria are not to be enrolled in this study.&#xD;
&#xD;
          1. Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study&#xD;
&#xD;
          2. Actively intoxicated.&#xD;
&#xD;
             Participants that meet any of the additional exclusion criteria are not to be treated&#xD;
             in this study.&#xD;
&#xD;
          3. History of any of the following:&#xD;
&#xD;
             b. Clinical hepatic compensation (i.e. ascites, encephalopathy or variceal&#xD;
             haemorrhage) c. Solid organ transplant d. History of severe, life-threatening or other&#xD;
             significant sensitivity to study drugs (glecaprevir/pibrentasvir/sofosbuvir) or any&#xD;
             excipients of the study drugs&#xD;
&#xD;
          4. Creatinine clearance (CLcr) &lt; 30 mL/min at screening (Cohort B only)&#xD;
&#xD;
          5. Pregnant or nursing female&#xD;
&#xD;
          6. Decompensated liver disease&#xD;
&#xD;
          7. Use of prohibited concomitant medications&#xD;
&#xD;
          8. Chronic use of systemically administered immunosuppressive agents (e.g. prednisone&#xD;
             equivalent &gt; 10 mg/day for &gt;2 weeks)&#xD;
&#xD;
          9. Prior treatment failure with an NS5A based DAA regimen&#xD;
&#xD;
        Patients without an IRID but who fulfill all other criteria and are admitted with an&#xD;
        expected duration of stay &gt; 1 week may also be included at discretion of study team.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amanda Erratt</last_name>
    <phone>61 2 9385 0882</phone>
    <email>aerratt@kirby.unsw.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pip Marks</last_name>
    <phone>61 2 9385 0886</phone>
    <email>pmarks@kirby.unsw.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Post</last_name>
      <email>Jeffrey.Post@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Post</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Matthews</last_name>
      <email>gmatthews@kirby.unsw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Gail Matthews, MBChB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blacktown Mt Druitt Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Golo Ahlenstiel, MD</last_name>
      <email>golo.ahlenstiel@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Golo Ahlenstiel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Douglas</last_name>
      <email>mark.douglas@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Mark Douglas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily Rowe</last_name>
      <email>emily.rowe@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Emily Rowe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Doyle</last_name>
      <email>joseph.doyle@burnet.edu.au</email>
    </contact>
    <investigator>
      <last_name>Joseph Doyle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Thompson</last_name>
      <email>Alexander.THOMPSON@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Alexander Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>people who inject drugs</keyword>
  <keyword>injecting related infectious diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

